According to a new report Europe Continuous Glucose Monitoring Device Market, published by KBV research, the Europe Continuous Glucose Monitoring Device Market would witness market growth of 12% CAGR during the forecast period (2020-2026).
The Germany market is one of the major regions within the Europe Other End Users Market by Country in 2019, growing at a CAGR of 12.1 % during the forecast period. The UK market is projected to grow at a CAGR of 11.8% during (2020 - 2026). Additionally, The France market is witnessing a CAGR of 14.3% during (2020 - 2026).
The Sensors market dominated the France Continuous Glucose Monitoring Device Market by Component in 2019, growing at a CAGR of 13 % during the forecast period. The Transmitters market would exhibit a CAGR of 14.1% during (2020 - 2026). Additionally, The Receivers market is showcasing highest CAGR of 14.4% during (2020 - 2026).
The Homecare Settings market dominated the Spain Continuous Glucose Monitoring Device Market by End-user in 2019, thereby, achieving a market value of $87.9 million by 2026. The Hospitals market is experiencing a CAGR of 13.1% during (2020 - 2026). The Other End Users market is expected to witness a CAGR of 13.9% during (2020 - 2026).
Structural Insights: https://www.kbvresearch.com/europe-continuous-glucose-monitoring-device-market/
The market research report has exhaustive quantitative insights providing a clear picture of the market potential in various segments across the mentioned countries. The key impacting factors of the market have been discussed in the report with the elaborated company profiles of Abbott Laboratories, Medtronic PLC, F. Hoffmann-La Roche Ltd., Novo Nordisk A/S, DexCom, Inc., Ypsomed AG, Senseonics Holdings, Inc., GlySens, Incorporated, A. Menarini Diagnostics Ltd. (The Menarini Group), Echo Therapeutics, Inc., Johnson and Johnson.
By Component
By End User
By Country
Companies Profiled
Unique Offerings from KBV Research
Unique Offerings 
